A Comparison of Combination Chemotherapy with TP and PAC in the Treatment of Primary Peritoneal Malignancies

张超,崔恒,赵彦,梁旭东,王朝华,李小平,沈丹华,王世军,魏丽惠

DOI: https://doi.org/10.3969/j.issn.1672-1861.2005.05.002

2005-01-01

Abstract:Objective To explore and compare the effects of different chemotherapy regimens on the survival of patients with primary peritoneal neoplasms. Methods We retrospectively reviewed the clinical and pathological records of 27 cases of primary peritoneal neoplasm treated in Peking University People's Hospital from May 1995 to May 2005. Results All patients underwent cytoreductive surgery and received a latinum-based combination chemotherapy. Twenty-four cases received paclitaxel+cisplatin (TP) or cisplatin+doxorubicin+ cyclophosphamide (PAC) regimen, among whom 2 haven't completed the chemotherapy and 2 were lost of follow-up. The other 2 received another platinum-based regimens and 1 didn't receive chemotherapy. Among the 20 cases with detailed clinical records, 13 patients received TP and 7 received PAC chemotherapy. The primary response was 80% (complete response 60% and partial response 20%). The median progression-free survival and overall survival of all patients was 16 months and 42 months respectively. The TP and PAC groups were well matched with respect to the mean age, menopause, ascitic cytology test, residual tumor size, stage, pathological types, chemotherapy courses and toxicity. The median progression-free survival for the TP and PAC groups were 19 and 12 months. No significant difference was achieved. However, patients receiving TP combination exhibited longer survival than those receiving PAC regimen (mean survival 69 vs 28 months, P0.05).Conclusions Cytoreductive surgery and a platinum-based combination chemotherapy may improve the prognosis of patients with primary peritoneal malignancies. TP regimen can obtain longer survival than PAC regimen.